Today: 11 June 2026
Browse Category

Pharmaceutical Industry 28 December 2025 - 10 January 2026

Thermo Fisher Scientific Inc stock: Weaverville phase-out plan hits tape ahead of JPM talk, Jan. 29 earnings

Thermo Fisher Scientific Inc stock: Weaverville phase-out plan hits tape ahead of JPM talk, Jan. 29 earnings

Thermo Fisher Scientific will close its Weaverville, N.C., facility by late 2027, cutting 421 jobs starting December 2026, according to a WARN notice. Shares rose 2.04% Friday to $618.86, near a record high. The company will report earnings Jan. 29 and CEO Marc Casper is scheduled to speak at the J.P. Morgan Healthcare Conference on Jan. 13.
10 January 2026
···
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie shares fell 1.8% to $220.08 after the company cut its 2025 earnings forecast and denied takeover talks with Revolution Medicines. AbbVie now expects Q4 adjusted EPS of $2.61–$2.65, down from $3.32–$3.36, and full-year EPS of $9.90–$9.94. The company cited $1.265 billion in R&D and milestone charges. AbbVie said its fourth-quarter results are preliminary.
10 January 2026
···
Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly shares fell nearly 2% to $1,063.56 Friday, logging a second straight decline after hitting a 52-week high Thursday. The drop followed news that its Zepbound-Taltz drug combo outperformed Taltz alone in a late-stage trial, and a $1.2 billion deal to buy Ventyx Biosciences. Investors are watching for pricing pressures in Europe and key support near $1,060. Lilly’s next earnings call is Feb. 4.
9 January 2026
·
Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines shares rose 4.3% to $112.00 Friday after reports that Merck is in talks to buy the company for up to $32 billion. The FDA granted Breakthrough Therapy designation to Revolution’s KRAS-targeting lung cancer drug this week. AbbVie denied involvement in any deal. Revolution declined to comment on the takeover speculation.
9 January 2026
··
Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly shares fell 2.1% after hours to $1,085.19 following late-stage data showing its Zepbound-Taltz combo met dual goals in 31.7% of psoriatic arthritis patients, versus 0.8% for Taltz alone. The company also agreed to buy Ventyx Biosciences for $1.2 billion and disclosed a $322.4 million share sale by Lilly Endowment Inc. Investors await updates at the J.P. Morgan Healthcare Conference next week.
9 January 2026
··
Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

Arcus Biosciences shares dropped 9.3% to $21.05 Thursday after Morgan Stanley downgraded the stock and cut its price target to $20. The company highlighted a February data update and a Jan. 14 J.P. Morgan conference slot. BlackRock disclosed a 10.4% stake as of Dec. 31. President Juan C. Jaen reported selling 31,823 shares on Jan. 5 under a pre-set trading plan.
8 January 2026
··
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Eli Lilly agreed to acquire Ventyx Biosciences for $14 per share in cash, valuing the company at about $1.2 billion. Ventyx shares closed up 37% at $13.81, while Lilly rose 4%. The deal is expected to close in the first half of 2026, pending shareholder approval. Investors await proxy filings and Lilly’s next earnings call for further details.
7 January 2026
···
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics shares dropped 5.3% to $36.09 Tuesday ahead of the FDA’s Jan. 13 decision on expanding kidney drug Filspari’s label. Options trading surged, with heavy put activity at the $35 strike. Chief Medical Officer Jula Inrig disclosed a planned sale of 15,000 shares to cover taxes. CEO Eric Dube will present at the J.P. Morgan Healthcare Conference on Jan. 12.
6 January 2026
··
JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

Johnson & Johnson shares dropped 2.2% to $202.86 Monday, underperforming a rising market as investors rotated out of healthcare stocks. The move comes ahead of key events including the Jan. 9 U.S. jobs report and J&J’s Jan. 21 earnings call. More than 67,000 talc lawsuits remain unresolved, with a special master set to review expert evidence in New Jersey federal court.
5 January 2026
···
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics shares surged 23% to $182.64 after the FDA accepted its supplemental application for AXS-05 in Alzheimer’s agitation and granted priority review. The stock traded on heavy volume, swinging between $148.79 and $184.40. Axsome also said its AXS-12 narcolepsy drug remains on track for a January 2026 filing. Markets will reopen Friday after the New Year’s Day holiday.
1 January 2026
···
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept shares closed down 50.4% at $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing insufficient evidence. Truist cut its price target to $50 and Wolfe downgraded the stock to Underperform with a $30 target. The FDA set a July 11, 2026 decision date for relacorilant in ovarian cancer. U.S. markets are closed Thursday for New Year’s Day.
1 January 2026
··
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept shares plunged about 50% in after-hours trading after the FDA declined to approve relacorilant for hypertension linked to hypercortisolism. The agency requested more evidence of effectiveness, despite acknowledging trial data. Wolfe Research downgraded the stock and slashed its price target. Corcept said it plans to meet with the FDA to discuss next steps.
1 January 2026
··
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
30 December 2025
··
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics shares fell 3.3% to $35.61 by early afternoon Tuesday, underperforming biotech peers as investors awaited updates on its blood-pressure drug lorundrostat. The stock remains up 183% over 52 weeks but is down 25% from its November high. Mineralys plans to file for FDA approval of lorundrostat by early 2026 and expects Phase 2 results in the first quarter of that year.
30 December 2025
··
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept Therapeutics shares fell 8.9% to $72.72 in early afternoon trading Tuesday as investors awaited the FDA’s decision on relacorilant, due later in the day. SEC filings showed CEO Joseph Belanoff and Chief Business Officer Gary Charles Robb exercised stock options and withheld shares for taxes. About 897,000 shares changed hands. The drop outpaced declines in major biotech indexes.
30 December 2025
··
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines shares jumped 13% to $304.58 after the FDA granted Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The stock traded between $318.08 and $275.00 during the session. Praxis said it plans to file a New Drug Application in early 2026. Analyst BTIG raised its price target on Praxis to $843.
30 December 2025
··
Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly shares closed at $1,077.75 Friday, near record highs, as U.S. markets shut for the weekend. ABL Bio announced $55 million in new funding tied to Lilly, including a $40 million upfront payment and $15 million equity investment. Investors remain focused on obesity-drug momentum and the FDA’s recent approval of Novo Nordisk’s weight-loss pill.
28 December 2025
·
1 2 3 4 5 6 … 9

Stock Market Today

  • Telesat (TSAT) Valuation Assessed After Significant Share Price Increase
    June 10, 2026, 7:32 PM EDT. Telesat (TSAT) shares surged 405% over three years but dropped 20% last month, trading at $43.89. The company reports CA$388.3 million revenue with a CA$185.3 million loss. Telesat's Price-to-Sales (P/S) ratio stands at 2.4x, above the US Telecom average of 1.3x and peer average of 2.3x, indicating relatively high investor expectations. However, a regression-based fair P/S of 8.8x suggests the market may undervalue future growth if assumptions hold. Risks include dependence on Geostationary Earth Orbit (GEO) revenue and potential setbacks in Low Earth Orbit (LEO) projects. Investors are advised to weigh the significant potential upside against these operational challenges and market sentiment.

Latest articles

Lloyds stock drifts lower as FCA car finance hold clouds buyback hopes

Lloyds stock drifts lower as FCA car finance hold clouds buyback hopes

11 June 2026
Lloyds shares fell 0.98% as the FCA told Parliament that motor-finance compensation payments are now unlikely before 2027 due to legal challenges, prolonging uncertainty over redress costs and capital returns; investors must wait for clarity, with the next key update due July 30.
Nokia Slides, Nvidia AI-RAN Trade Cools Ahead of Key Test

Nokia Slides, Nvidia AI-RAN Trade Cools Ahead of Key Test

11 June 2026
Nokia’s U.S. ADR plunged 3.25% to $13.40, extending losses after a 5.07% drop, as investors reacted to risks from Nvidia’s push into mobile-network tech, raising doubts about Nokia’s role in AI infrastructure and overshadowing new 5G and AI product launches; shares now sit 23% below last week’s high.
Go toTop